RetiredUnitedHealthcarePolicy CS082LA.R

Neurophysiologic Testing and Monitoring (for Louisiana Only)

State-specific UnitedHealthcare medical policy governing neurophysiologic/electrodiagnostic testing and monitoring for Louisiana members (effective June 1, 2025 - March 31, 2026). It defines proven/medically necessary indications and lists tests/procedures considered unproven/not medically necessary, with applicable CPT/HCPCS codes and performance/supervision guidance.

Policy Summary

PayerUnitedHealthcare

PolicyNeurophysiologic Testing and Monitoring (for Louisiana Only)

Policy CodePolicy CS082LA.R

Change TypeRetiredcoding and coverage examples updated (06/01/2025)

Effective DateJun 1, 2025

Next Review Date

Key ActionThis medical policy applies only to the state of Louisiana; ensure state-specific benefit application.

SourceLink

POLICY UPDATE CHANGES

Policy marked as retired effective April 1, 2026; effective coverage window was June 1, 2025 - March 31, 2026.

Retired policy; Louisiana plan membership disenrolled on Apr. 1, 2026.

Coverage Rationale: Removed list of examples of non-invasive automatic, portable, or automated point of care nerve conduction monitoring systems.

Applicable Codes: Updated list of applicable CPT codes to reflect annual edits; removed 96003.

Supporting Information: Updated Clinical Evidence and References sections to reflect current information (06/01/2025).

11Listed proven/medically necessary indications (high-level)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Listed unproven/not medically necessary tests

40Number of procedure codes listed

>=2.1/24hTypical false alarm rate reported for wearables (per 24 h)

1Policy retirement event (Louisiana) 2026-04-01

Coverage Summary

This Louisiana‑specific UnitedHealthcare medical policy governed neurophysiologic/electrodiagnostic testing and monitoring for Louisiana members from June 1, 2025 through March 31, 2026, and is marked RETIRED effective April 1, 2026 for Louisiana membership. Coverage stance for the policy is mixed, listing 11 proven/medically necessary indications, 10 tests/procedures considered unproven/not medically necessary, and referencing approximately 40 procedure codes in the included code list.

Medical-Necessity Criteria

Not Medically Necessary / Unproven

Evidence, Device Regulation, and Technological Summaries

The policy defines the role and supporting evidence for electrodiagnostic testing including nerve conduction studies (NCS) — with assessment of conduction velocity, latency, amplitude and optional late responses (F‑wave, H‑reflex) — and needle electromyography (EMG), as well as neuromuscular junction testing (repetitive stimulation/SFEMG). It also addresses emerging and portable technologies such as point‑of‑care/automated NCS devices, wearable physiologic seizure/movement monitors, surface EMG (sEMG) and surface mechanomyography (sMMG), quantitative sensory testing (QST), and visual evoked potentials (VEP/icVEP). The policy references AANEM guidance on proper performance, supervision, and minimum standards for EDX testing and personnel qualifications.

Coding

Included CPT / HCPCS / Other codes (reference list)mixed

0106T	Quantitative sensory testing (QST), testing and interpretation per extremity; using touch pressure stimuli to assess large diameter sensation.
0107T	Quantitative sensory testing (QST), testing and interpretation per extremity; using vibration stimuli to assess large diameter fiber sensation.
0108T	Quantitative sensory testing (QST), testing and interpretation per extremity; using cooling stimuli to assess small nerve fiber sensation and hyperalgesia.
0109T	Quantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia.
0110T	Quantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensation.
0464T	Visual evoked potential, testing for glaucoma, with interpretation and report.
0778T	Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU) sensors for measurement of multi-joint range of motion, posture, gait, and muscle function.
95860	Needle electromyography; 1 extremity with or without related paraspinal areas.
95861	Needle electromyography; 2 extremities with or without related paraspinal areas.
95863	Needle electromyography; 3 extremities with or without related paraspinal areas.

1–10 of 39

1/4

Applicable CPT/HCPCS/Other codes (policy notes indicate annual updates; specific codes updated on 06/01/2025)mixed

No codes listed

FDA product codes / 510(k) identifiers referencedmixed

IKN	EMG devices (FDA product code).
GWE	Evoked response photic stimulators (FDA product code).
HLX	Evoked response photic stimulators (FDA product code).
GWQ	EEG/evoked response recording devices (FDA product code).
LLN	Vibration threshold measurement device / QST (FDA product code).
GXB	Esthesiometer / QST (FDA product code).
LQW	Temperature discrimination test / QST (FDA product code).
GWI	2-point discriminator / QST (FDA product code).
JXE	Point-of-care nerve conduction devices (FDA product code).
K934368	PSSD FDA 510(k) number (approved Aug 11, 1994).

1–10 of 15

1/2

Applicable CPT/HCPCS codes are updated annually to reflect AMA/CPT edits; the policy notes coding updates on 06/01/2025 and specifically removed 96003 from the applicable codes list effective that date.

Provider Actions & Billing Guidance

Documentation Required

Indication documentation

Document the specific known or suspected neurologic disorder (e.g., peripheral neuropathy, plexopathy, myopathy, neuromuscular junction disorder, motor neuron disease, radiculopathy) in the medical record to justify electrodiagnostic (EDX) testing. Include pertinent history, focused neurological exam findings, and how the results will influence diagnosis or management.

Documentation Required

Clinical indication for NCS without EMG

Nerve conduction studies (NCS) performed without needle EMG are allowable only when one of the following clinical conditions is present: current anticoagulant therapy that increases bleeding risk, documented lymphedema of the limb being tested, or evaluation specifically for carpal tunnel syndrome. Document the clinical rationale and why needle EMG is contraindicated or not required.

Allowed indications for NCS without EMG: anticoagulant therapy; lymphedema; carpal tunnel syndrome

Documentation Required

Supervision and performance

Definitions & Evidence Highlights

Glossary: NCS — nerve conduction studies assessing conduction velocity, latency, and amplitude; may include late responses (F‑wave, H‑reflex).

EMG — electromyography including needle EMG (NEMG) and surface EMG (SEMG).

Point‑of‑care NCS — non‑invasive automatic or portable nerve conduction systems that test distal motor latencies and conduction velocities without producing real‑time waveforms.

FAR — False Alarm Rate per 24 hours; GTCS — generalized tonic‑clonic seizure; FBTCS — focal to bilateral tonic‑clonic seizure.

QST — quantitative sensory testing (e.g., monofilament, vibration, thermal, CPT/sNCT).

sEMG — surface electromyography; sMMG — surface mechanomyography.

icVEP — isolated‑check visual evoked potential (a VEP variant using SNR as a diagnostic metric).

PSSD — Pressure‑Specified Sensory Device (FDA 510(k) cleared neurosensory testing system).

Evidence item	Key finding
Wearable seizure detection sensitivity (meta-analysis)	Pooled sensitivity for tonic-clonic seizures ~0.91 (95% CI 0.85–0.96); overall false alarm rate (FAR) ~2.1/24 h; wrist-worn sensitivity .93 with FAR 2.5/24 h, surface devices sensitivity .90 with FAR .96/24 h.
Electrodermal response incidence	Pooled EDA response incidence 82/100 seizures (95% CI 70–91); TCS/FBTCS elicit more pronounced EDA responses versus focal seizures.
sEMG EMU phase III results (Halford et al. 2017)	Overall detected 35/46 GTCS (76%); when placed over biceps midline detected 29/29 (100%) with mean detection delay 7.70 s, PPV 6.2%, FAR 1.44/24 h; mild-moderate skin irritation in 28%.
PKG clinical impact (Santiago et al. 2019)	In physician surveys (n=112), PKG provided relevant additional information in 41% of cases; of those, 78% led to management changes (36/46 surveys resulting in adjustments).
KinetiGraph classifier accuracy (Khodakarami et al. 2019)	Classifier sensitivity 89% and specificity 86.6%; identified device-assisted therapy (DAT) candidates in 87–100% across subgroups; score changed appropriately after interventions.
Monofilament diagnostic accuracy (Wang et al. 2017)	Pooled sensitivity 0.53 and specificity 0.88 for detecting diabetic peripheral neuropathy; limited sensitivity for screening.
icVEP small cross-sectional studies — Wang et al. (2020)	In N=126 study, icVEP (SNR ≤1) showed diagnostic potential to distinguish POAG in high myopia with AUC comparable to OCT/HRT; limited by small sample and cross-sectional design.
icVEP small cross-sectional studies — Fan et al. (2018)	Study (37 OAG, 26 controls) reported sensitivity 62.2% and specificity 92.3% at SNR ≤1; ROC suggested SNR 0.93 improves classification; small sample limits conclusions.
icVEP small cross-sectional studies — Xu et al. (2017)	N=90 POAG, 66 controls: reported AUC 0.79 with cutoff SNR 0.85 (sensitivity 91.1%, specificity 69.7%); sample size limits generalizability.
icVEP comparisons (Chen & Zhao 2017a/2017b)	Small studies found icVEP diagnostic power similar to GCIPL analysis and SAP in limited samples (e.g., sensitivity ~80% and specificity ~90% in one comparison); evidence insufficient for coverage decisions.

Revision History

2026-04-01retirementLatest

Policy marked as retired; Louisiana plan membership disenrolled on Apr. 1, 2026 (Retired April 1, 2026).

2025-06-01effective_period_start

Policy became effective for the coverage window beginning June 1, 2025 (Effective Date: June 1, 2025 - March 31, 2026).

2026-03-31effective_period_end

Policy Summary

PayerUnitedHealthcare

PolicyNeurophysiologic Testing and Monitoring (for Louisiana Only)

Policy CodePolicy CS082LA.R

Change TypeRetiredcoding and coverage examples updated (06/01/2025)

Effective DateJun 1, 2025

Next Review Date

Key ActionThis medical policy applies only to the state of Louisiana; ensure state-specific benefit application.

SourceLink

On This Page

Follow AANEM guidance: electrodiagnostic testing should be supervised and/or performed by a physician trained in electrodiagnostic medicine. Individuals trained to perform portions of testing must work under the direct supervision of such a physician, and the physician must review and interpret the complete study.

Physician trained in electrodiagnostic medicine required
Direct supervision for trained non-physician performers; physician review/interpretation required

Billing Rule

Applicable codes updated annually

CPT and other procedure codes are updated annually; verify current code set at time of service. Note: CPT code 96003 has been removed effective 2025-06-01 and should not be billed after that date.

CPT updates effective annually
96003 removed 06/01/2025

Denial Risk

FDA clearance informational only

FDA clearance or marketing authorization alone does not establish that a device or service meets coverage criteria. Coverage and payment require that the service meet the policy's medical necessity criteria; claims for devices or services that do not meet these criteria may be denied despite FDA clearance.

FDA clearance is informational only and not sufficient for coverage
Claims may be denied if coverage criteria are not met

Documentation Required

State applicability and retirement / plan disenrollment notice (Louisiana)

This policy applies only to UnitedHealthcare membership in Louisiana. The policy is retired effective April 1, 2026; members covered under this policy may be disenrolled or transitioned consistent with plan and state requirements. Providers should verify member eligibility and plan-specific enrollment impacts prior to providing services.

Applies only to Louisiana membership
Policy retirement effective 2026-04-01; may affect disenrollment and transition of benefits

Documentation Required

Use guideline-endorsed devices for GTCS detection

For generalized tonic-clonic seizure (GTCS) detection, use devices endorsed by guideline statements and supported by evidence for GTCS detection. Ensure device selection and use align with published clinical guidance and the device's intended use.

Use guideline-endorsed devices for GTCS detection

Documentation Required

Limitations of wearables for other seizure types

Current wearable seizure-detection devices (accelerometers, electrodermal sensors, gyroscopes, wrist devices, smartwatches) have limitations and are not proven for detecting non-GTCS seizure types. Document the device limitations and do not rely on wearables as sole diagnostic evidence for other seizure types.

Wearables limited for detection of seizure types other than GTCS

Documentation Required

Interpret QST cautiously

Quantitative sensory testing (QST) results should be interpreted cautiously and in the context of the clinical examination and other diagnostic studies. QST alone is considered unproven for many indications and must be correlated with clinical findings.

Interpret QST results cautiously and correlate with clinical findings

Documentation Required

sEMG monitoring tolerability and false alarms

Surface EMG (sEMG) monitoring may have tolerability issues and a risk of false alarms. Document patient tolerance, device positioning, and any false-positive or false-negative events when used for monitoring.

sEMG monitoring: document tolerability and note potential for false alarms

Documentation Required

Reference federal/state/contractual benefit terms

Benefit coverage is governed by applicable federal, state, and contractual terms. Always confirm coverage determinations against member-specific plan benefits and state Medicaid fee schedules where relevant.

Reference federal/state/contractual benefit terms for coverage determination

Documentation Required

Use of third-party clinical criteria

Some services referenced in this policy may be subject to third-party clinical criteria or management programs. When applicable, follow the specified external clinical criteria in addition to this policy.

Use of third-party clinical criteria when applicable

Coverage window end date March 31, 2026 (Effective Date: June 1, 2025 - March 31, 2026).

2025-06-01revised_coverage_rationale

Coverage Rationale: Removed the list of example automated/point-of-care nerve conduction monitoring systems (NC-stat System, Brevio NCS-Monitor, Advance System).

2025-06-01coding_update

Applicable Codes: Updated list of applicable CPT/HCPCS codes to reflect annual edits; removed CPT code 96003.

2025-06-01supporting_info_update

Supporting Information: Clinical evidence and references updated; prior policy version CS082LA.Q archived.

policy_scope_note

Policy applies only to the state of Louisiana and defines medically necessary and not medically necessary electrodiagnostic and physiologic monitoring tests (includes point-of-care NCS, sEMG/sMMG, QST, VEP) per stated criteria.